References
- Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20. doi:https://doi.org/10.1016/S0140-6736(10)62307-0
- Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26. doi:https://doi.org/10.1038/s41571-018-0112-1
- Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;24(10):2484–92. doi:https://doi.org/10.1093/annonc/mdt239
- Shukla SK, Dasgupta A, Mulder SE, Singh PK. Molecular and physiological evaluation of pancreatic cancer-induced cachexia. Methods Mol Biol. 2019;1882:321–33. doi:https://doi.org/10.1007/978-1-4939-8879-2_28
- Carrara G, Pecorelli N, De Cobelli F, Cristel G, Damascelli A, Beretta L, Braga M. Preoperative sarcopenia determinants in pancreatic cancer patients. Clin Nutr. 2017; 36(6):1649–53. doi:https://doi.org/10.1016/j.clnu.2016.10.014
- Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, Hong TH, Choi M-G. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):326–34. doi:https://doi.org/10.1002/jcsm.12274
- Basile D, Parnofiello A, Vitale MG, Cortiula F, Gerratana L, Fanotto V, Lisanti C, Pelizzari G, Ongaro E, Bartoletti M, et al. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. J Cachexia Sarcopenia Muscle. 2019;10(2):368–77. doi:https://doi.org/10.1002/jcsm.12368
- Gruber ES, Jomrich G, Tamandl D, Gnant M, Schindl M, Sahora K. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. PLoS One. 2019;14(5):e0215915. doi:https://doi.org/10.1371/journal.pone.0215915
- Naumann P, Eberlein J, Farnia B, Hackert T, Debus J, Combs SE. Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Cancers (Basel). 2019;11(5):709. doi:https://doi.org/10.3390/cancers11050709
- Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol. 2015; 22(7):2416–23. doi:https://doi.org/10.1245/s10434-014-4285-2
- Cloyd JM, Nogueras-González GM, Prakash LR, Petzel MQB, Parker NH, Ngo-Huang AT, Fogelman D, Denbo JW, Garg N, Kim MP, et al. Anthropometric changes in patients with pancreatic cancer undergoing preoperative therapy and pancreatoduodenectomy. J Gastrointest Surg. 2018;22(4):703–12. doi:https://doi.org/10.1007/s11605-017-3618-4
- Sandini M, Patino M, Ferrone CR, Alvarez-Pérez CA, Honselmann KC, Paiella S, Catania M, Riva L, Tedesco G, Casolino R, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018;153(9):809–15. doi:https://doi.org/10.1001/jamasurg.2018.0979
- Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J-C, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, et al. 3D slicer as an image computing platform for the quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323–41. doi:https://doi.org/10.1016/j.mri.2012.05.001
- Baracos VS, Beaumont CE, Lieffers JM. Quality Assurance and Training Manual - Body Composition Analysis Using Computed Tomography (CT) Imaging Version 1.4. 2014.
- Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83–96.
- Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. JCO. 2013;31(12):1539–47. doi:https://doi.org/10.1200/JCO.2012.45.2722
- Kays JK, Shahda S, Stanley M, Bell TM, O'Neill BH, Kohli MD, Couch ME, Koniaris LG, Zimmers TA. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(4):673–84. doi:https://doi.org/10.1002/jcsm.12307
- Kassambara A, Kosinski M. Survminer: drawing survival curves using “ggplot2,” https://CRAN.R-project.org/package=survminer. R package version 0.4, 2018, p. 3.
- Wickham H. ggplot2. WIREs Comp Stat. 2011; 3(2):180–5. doi:https://doi.org/10.1002/wics.147
- Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, Neuzillet C, Goldwasser F. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology. Pharmacol Ther. 2019; 196:135–59. doi:https://doi.org/10.1016/j.pharmthera.2018.12.003
- Bijlsma AY, Meskers CGM, Ling CHY, Narici M, Kurrle SE, Cameron ID, Westendorp RGJ, Maier AB. Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. Age (Dordr)). 2013; 35(3):871–81. doi:https://doi.org/10.1007/s11357-012-9384-z
- Penna F, Ballarò R, Beltrà M, De Lucia S, García Castillo L, Costelli P. The skeletal muscle as an active player against cancer cachexia. Front Physiol. 2019;10:41. doi:https://doi.org/10.3389/fphys.2019.00041
- Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015; 22:100–6. doi:https://doi.org/10.1016/j.coph.2015.04.003
- Bundred J, Kamarajah SK, Roberts KJ. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford). 2019; 21(12):1603–12. doi:https://doi.org/10.1016/j.hpb.2019.05.018
- Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Australian Pancreatic Cancer Genome Initiative, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. doi:https://doi.org/10.1038/nature16965
- Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013; 10(2):90–9. doi:https://doi.org/10.1038/nrclinonc.2012.209
- Aversa Z, Costelli P, Muscaritoli M. Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol. 2017; 9(5):369–82. doi:https://doi.org/10.1177/1758834017698643
- Neto NIP, Murari A. S d P, Oyama LM, Otoch JP, Alcântara PSM, Tokeshi F, Figuerêdo RG, Alves MJ, Lima JDCC, Matos-Neto E. M d, et al. Peritumoural adipose tissue pro-inflammatory cytokines are associated with tumoural growth factors in cancer cachexia patients. J Cachexia Sarcopenia Muscle. 2018; 9(6):1101–8. doi:https://doi.org/10.1002/jcsm.12345
- Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–7.e2. doi:https://doi.org/10.1016/j.jamda.2019.12.012
- Xia MF, Chen LY, Wu L, Ma H, Li XM, et al. Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: a cross-sectional study. Clin Nutr. 2020. doi:https://doi.org/10.1016/j.clnu.2020.06.003
- Grillot J, D'Engremont C, Parmentier Al Lakkis Z, Piton G, et al. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease. Clin Nutr. 2020;39:3024–3030. doi:https://doi.org/10.1016/j.clnu.2020.01.001
- Yoon HG, Oh D, Ahn YC, Noh JM, Pyo H, Cho WK, Song YM, Park M, Hwang NY, Sun J-M, et al. Prognostic impact of sarcopenia and skeletal muscle loss during neoadjuvant chemoradiotherapy in esophageal cancer. Cancers (Basel). 2020;12(4):925. doi:https://doi.org/10.3390/cancers12040925
- Tan BHL, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015; 41(3):333–8. doi:https://doi.org/10.1016/j.ejso.2014.11.040
- Zhang S, Tan S, Jiang Y, Xi Q, Meng Q, Zhuang Q, Han Y, Sui X, Wu G. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study. Clin Nutr. 2019; 38(6):2881–8. doi:https://doi.org/10.1016/j.clnu.2018.12.025
- Uemura S, Iwashita T, Ichikawa H, et al. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr. 2020. doi:https://doi.org/10.1017/S0007114520003463
- Yamazaki H, Sugino K, Matsuzu K, Masaki C, Akaishi J, Hames K, Tomoda C, Suzuki A, Uruno T, Ohkuwa K, et al. Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas. Endocrine. 2020; 68(1):132–7. doi:https://doi.org/10.1007/s12020-019-02162-x
- Endo K, Kuroda H, Kanazawa J, Sato T, Fujiwara Y, Abe T, Sato H, Kooka Y, Oikawa T, Sawara K, et al. Impact of grip strength in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Cancers (Basel). 2020; 12(8):2146. doi:https://doi.org/10.3390/cancers12082146
- Molfino A, Amabile MI, Muscaritoli M. Nutrition support for treating cancer-associated weight loss: an update. Curr Opin Support Palliat Care. 2018;12(4):434–8. doi:https://doi.org/10.1097/SPC.0000000000000383